Archive: 18/08/2020
Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations
In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, achieved a 51% overall response rate (ORR) in ...
Aug 18, 2020